An Outline of the Immunogenic Potential of Progressing SARSCoV-
2 Vaccine Technologies among Children and Adolescents

Hytham      Ghanem; Shehab      Ghanem; Ehsan      AlMutawa

doi:10.2174/1872208317666230612141930

Abstract

Background: SARS-CoV-2, a highly dynamic beta-coronavirus, can afflict all age groups. Notably, over 16100 mortalities have been recorded among children as yet. In this regard, many vaccine projects are operational to assess immuno-potency among young cohorts. A bulk of reports have evidenced the efficacy of these immunization technologies in the elderly population, though the impact is yet to be determined among children.

Objectives: This review is envisioned to outline the current efficacy of contributing vaccine technologies and examine the dose-dependent impact of immunization regimens in lowering the risks of SARS-CoV-2 infections among children and adolescents. Furthermore, the current review exclusively estimated the vaccine impact at current doses.

Methods: A total of 52 research papers extracted from PubMed, Pubmed Central, Science Direct, Research Gate, Google Scholar and Semantic Scholar were screened along with an emphasis on patents. Inclusion criteria involved all published reports directly or indirectly linked to the contributing vaccine candidates that are operational among the young cohort. Unrelated research papers were excluded from the study. Key search terminologies included information on vaccine identifiers, such as name, type and clinical trial ID, and successively restricted to children and adolscents age groups.

Results: Several vaccine designs, such as mRNA-based vaccinations, viral vector vaccines, DNA vaccines, inactivated vaccines, recombinant vaccines, and protein-based immunizations, are being examined at various stages of clinical trials to gauge the effects on children and adolescents. With reference to the published reports, the mRNA 1273 (1610 GMT; 6-10 yrs, 1401 GMT; 12-15 yrs), BNT162b2 (1407 GMT; 6 months- <2 yrs, 1535 GMT; 2-4 yrs, 4583 GMT; 5-11 yrs, 1239.5 GMT; 12-15 yrs) and Ad5 nCoV (1037.5 GMT; 6-17 yrs) offered relatively high neutralization titers with sharp seroconversion rates compared to MVC-COV1901 (648.5 GMT; 12-17 yrs) and ZyCoV-D (133.49 GMT; 12-17 yrs), which produced modest immune responses.

Conclusion: Currently, the WHO is analyzing emerging evidence to issue an emergency use list of vaccines for vaccinating children and adolescents.

Keywords: Children, adolescents, COVID‐19 vaccines, immunization technologies, SARS-CoV-2, vaccines.

« Previous Next »

Graphical Abstract

[1]
Naz SS, Munir I. An overview of the treatment contributions measured globally for the COVID-19 Outbreak. Coronaviruses  2021; 2(2): 198-203.
 [http://dx.doi.org/10.2174/2666796701999201019154537]

[2]
Nathanielsz J, Toh ZQ, Do LAH, Mulholland K, Licciardi PV. SARS-CoV-2 infection in children and implications for vaccination. Pediatr Res  2023; 93(5): 1177-87.
 [http://dx.doi.org/10.1038/s41390-022-02254-x] [PMID: 35970935]

[3]
Li CX, Noreen S, Zhang LX, et al. A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies. Biomed Pharmacother  2022; 146: 112550.
 [http://dx.doi.org/10.1016/j.biopha.2021.112550] [PMID:  34959116]

[4]
Khemiri H, Ayouni K, Triki H, Haddad-Boubaker S. SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era. Virol J  2022; 19(1): 144.
 [http://dx.doi.org/10.1186/s12985-022-01873-4] [PMID:  36076271]

[5]
Florensa D, Mateo J, Spaimoc R, et al. Severity of COVID-19 cases in the months of predominance of the Alpha and Delta variants. Sci Rep  2022; 12(1): 15456.
 [http://dx.doi.org/10.1038/s41598-022-19125-4] [PMID:  36104358]

[6]
Arora A. COVID-19 confirmed cases and deaths. 2022.2022. Available from: https://data.unicef.org/resources/covid-19-confirmed-cases-and-deathsdashboard/

[7]
Child mortality and COVID-19. 2023.2023. Available from: https://data.unicef.org/topic/child-survival/covid-19/

[8]
Tsabouri S, Makis A, Kosmeri C, Siomou E. Risk factors for severity in children with coronavirus disease 2019. Pediatr Clin North Am  2021; 68(1): 321-38.
 [http://dx.doi.org/10.1016/j.pcl.2020.07.014] [PMID:  33228941]

[9]
Munir I, Naz SS. An outline of contributing vaccine technologies for SARS CoV2 advancing in clinical and preclinical phase-trials. Recent Pat Biotechnol  2022; 16(2): 122-43.
 [http://dx.doi.org/10.2174/1872208316666220118094344] [PMID:  35040422]

[10]
Muik A, Poran A, Sahin U, Swanson KA, Yang Q, Cai H. Coronavirus vaccine. Patent WO2023094713A2, 2023.

[11]
Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ  2022; 376: e069761.
 [http://dx.doi.org/10.1136/bmj-2021-069761] [PMID:  35264324]

[12]
Creech CB, Anderson E, Berthaud V, et al. Evaluation of mRNA-1273 COVID-19 vaccine in children 6 to 11 years of age. N Engl J Med  2022; 386(21): 2011-23.
 [http://dx.doi.org/10.1056/NEJMoa2203315] [PMID:  35544369]

[13]
Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age. N Engl J Med  2022; 386(1): 35-46.
 [http://dx.doi.org/10.1056/NEJMoa2116298] [PMID:  34752019]

[14]
Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med  2021; 385(24): 2241-51.
 [http://dx.doi.org/10.1056/NEJMoa2109522] [PMID:  34379915]

[15]
Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. N Engl J Med  2021; 385(3): 239-50.
 [http://dx.doi.org/10.1056/NEJMoa2107456] [PMID:  34043894]

[16]
Muñoz FM, Sher LD, Sabharwal C, et al. Evaluation of BNT162b2 COVID-19 vaccine in children younger than 5 years of age. N Engl J Med  2023; 388(7): 621-34.
 [http://dx.doi.org/10.1056/NEJMoa2211031] [PMID:  36791162]

[17]
A study to evaluate the immunogenicity and safety of a recombinant protein COVID-19 vaccine as a booster dose in population aged 12-17 years. 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT05345873

[18]
A study to evaluate safety and Effectiveness of mRNA-1273 COVID-19 vaccine in healthy children between 6 months of age and less than 12 years of age. 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT04796896

[19]
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med  2021; 384(5): 403-16.
 [http://dx.doi.org/10.1056/NEJMoa2035389] [PMID:  33378609]

[20]
Lozano-Dubernard B, Soto-Priante E, Sarfati-Mizrahi D, et al. Recombinant vaccine against COVID-19 in a viral vector. Patent WO2021229270A1, 2021.

[21]
Tucker S, Emery D. Chimeric adenoviral vectors. Patent WO2021248017A2, 2021.

[22]
Deng S, Liang H, Chen P, et al. Viral vector vaccine development and application during the COVID-19 pandemic. Microorganisms  2022; 10(7): 1450.
 [http://dx.doi.org/10.3390/microorganisms10071450] [PMID:  35889169]

[23]
Zhu F, Jin P, Zhu T, et al. Safety and immunogenicity of a recombinant adenovirus type-5–vectored coronavirus dis-ease 2019 (COVID-19) vaccine with a homologous prime-boost regimen in healthy participants aged ≥6 years: A ran-domized, double-blind, placebo-controlled, phase 2b trial. Clin Infect Dis  2022; 75(1): e783-91.
 [http://dx.doi.org/10.1093/cid/ciab845] [PMID:  34551104]

[24]
González S, Olszevicki S, Salazar M, et al. Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: A retrospective cohort study in Argentina. EClinicalMedicine  2021; 40: 101126.
 [http://dx.doi.org/10.1016/j.eclinm.2021.101126] [PMID:  34541480]

[25]
Study of Gam-COVID-Vac in Adolescents (OLSTAD). 2021. Available from: https://clinicaltrials. gov/ct2/show/NCT04954092

[26]
Shafaati M, Saidijam M, Soleimani M, et al. A brief review on DNA vaccines in the era of COVID-19. Future Virol 2021.
 [http://dx.doi.org/10.2217/fvl-2021-0170] [PMID:  34858516]

[27]
Khobragade A, Bhate S, Ramaiah V, et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet  2022; 399(10332): 1313-21.
 [http://dx.doi.org/10.1016/S0140-6736(22)00151-9] [PMID:  35367003]

[28]
Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults. JAMA  2021; 326(1): 35-45.
 [http://dx.doi.org/10.1001/jama.2021.8565] [PMID:  34037666]

[29]
Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (Coro-naVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis  2021; 21(12): 1645-53.
 [http://dx.doi.org/10.1016/S1473-3099(21)00319-4] [PMID:  34197764]

[30]
Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in peo-ple younger than 18 years: A randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis  2022; 22(2): 196-208.
 [http://dx.doi.org/10.1016/S1473-3099(21)00462-X] [PMID:  34536349]

[31]
Leung D, Rosa Duque JS, Yip KM, So HK, Wong WHS, Lau YL. Effectiveness of BNT162b2 and CoronaVac in chil-dren and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong. Commun Med  2023; 3(1): 3.
 [http://dx.doi.org/10.1038/s43856-022-00233-1] [PMID:  36604522]

[32]
Li ML, Shih SR, Tolbert BS, Brewer G. Enterovirus A71 vaccines. Vaccines (Basel)  2021; 9(3): 199.
 [http://dx.doi.org/10.3390/vaccines9030199] [PMID:  33673595]

[33]
Enterovirus type 71 vaccine (vero cell), Inactivated-Inlive®. 2016. Available from: http://www.sinovac. com/product/showproduct.php?id=42&lang=en

[34]
Immunogenicity and safety of COVID-19 vaccine, inactivated co-administration with ev71 vaccine (vero cell). 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT05107557

[35]
Safety and immunogenicity study of inactivated vaccine for prevention of COVID-19. 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT04551547

[36]
Study of inactivated sars-cov-2 vaccine (vero cells) in healthy population aged 3 to 17 years (COVID-19). 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT05003466

[37]
Jin L, Li Z, Zhang X, Li J, Zhu F. CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vac-cine against SARS-CoV-2. Hum Vaccin Immunother  2022; 18(6): 2096970.
 [http://dx.doi.org/10.1080/21645515.2022.2096970] [PMID:  35878789]

[38]
Efficacy, immunogenicity and safety of COVID-19 vaccine, inactivated in children and adolescents. 2023.https://clinicaltrials.gov/ct2/show/NCT04992260

[39]
Tanriover MD, Aydin OA, Guner R, et al. Efficacy, immunogenicity, and safety of the two-dose schedules of Turkovac versus Coronavac in healthy subjects: A randomized, observer-blinded, non-inferiority phase III trial. Vaccines (Basel)  2022; 10(11): 1865.
 [http://dx.doi.org/10.3390/vaccines10111865] [PMID:  36366373]

[40]
Efficacy, immunogenicity, and safety of TURKOVAC vaccine versus the coronavac vaccine against COVID-19 in healthy adolescent (12-18 years). 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT05230940

[41]
Tsang NNY, So HC, Cowling BJ, Leung GM, Ip DKM. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: A prospective cohort study. 2022; 23(4): 421-34.
 [http://dx.doi.org/10.1016/S1473-3099(22)00732-0] [PMID: 36521506]

[42]
Efficacy, immunogenicity and safety of inactivated vaccine (coronavac) against SARS-CoV-2 in children and adolescents (Curumim). 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT05225285

[43]
Comparison of the tolerability, safety, and immunogenicity of Shifa-Pharmed COVID-19 inactivated vaccine (CovIran) and Sinopharm vaccine in the healthy population aged 12 to 18 years: A doubleblind, randomized, active-controlled, Phase I-II clinical trial. 2021. Available from: https://en.irct.ir/trial/59490

[44]
Girard MP. Human immunodeficiency virus vaccines.Vaccines.  (6th ed.),  2013.
 [http://dx.doi.org/10.1016/B978-1-4557-0090-5.00054-9]

[45]
Yadav T, Srivastava N, Mishra G, et al. Recombinant vaccines for COVID-19. Hum Vaccin Immunother  2020; 16(12): 2905-12.
 [http://dx.doi.org/10.1080/21645515.2020.1820808] [PMID:  33232211]

[46]
Meng FY, Gao F, Jia SY, et al. Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal Transduct Target Ther  2021; 6(1): 271.
 [http://dx.doi.org/10.1038/s41392-021-00692-3] [PMID:  34267185]

[47]
Impact of topical tranexamic acid in breast reconstruction. Full Text View - ClinicalTrials.gov.  Available from: https://clinicaltrials.gov/ct2/show/.

[48]
Liang JG, Su D, Song TZ, et al. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in non-human primates. Nat Commun  2021; 12(1): 1346.
 [http://dx.doi.org/10.1038/s41467-021-21634-1] [PMID:  33649323]

[49]
A Clinical Trial to Evaluate the Recombinant SARSCoV-2 Vaccine (CHO Cell) for COVID-19. 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT04869592

[50]
Richmond P, Hatchuel L, Dong M, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet  2021; 397(10275): 682-94.
 [http://dx.doi.org/10.1016/S0140-6736(21)00241-5] [PMID:  33524311]

[51]
Safety and Immunogenicity of SCB-2019 in Children less then 18 Years of Age. 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT05193279

[52]
Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med  2021; 384(23): 2187-201.
 [http://dx.doi.org/10.1056/NEJMoa2101544] [PMID:  33882225]

[53]
Tian F, Yang R, Chen Z. Safety and efficacy of COVID‐19 vaccines in children and adolescents: A systematic review of randomized controlled trials. J Med Virol  2022; 94(10): 4644-53.
 [http://dx.doi.org/10.1002/jmv.27940] [PMID:  35705969]

[54]
Yan ZP, Yang M, Lai CL. COVID-19 vaccines: A review of the safety and efficacy of current clinical trials. Pharmaceuticals (Basel)  2021; 14(5): 406.
 [http://dx.doi.org/10.3390/ph14050406] [PMID:  33923054]

[55]
Liu LT, Chiu CH, Chiu NC, et al. Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: A randomized phase 2 trial. NPJ Vaccines  2022; 7(1): 165.
 [http://dx.doi.org/10.1038/s41541-022-00589-4] [PMID:  36526640]

[56]
Thuluva S, Paradkar V, Gunneri S, et al. Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vac-cine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study. Vaccine  2022; 40(49): 7130-40.
 [http://dx.doi.org/10.1016/j.vaccine.2022.10.045] [PMID:  36328879]

[57]
A study to evaluate UB-612 COVID-19 vaccine in adolescent, younger and elderly adult volunteers. 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT04773067

Rights & Permissions Print Cite

Article Metrics

18

2

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1872208317666230612141930	Print ISSN 1872-2083
Publisher Name Bentham Science Publisher	Online ISSN 2212-4012

Recent Patents on Biotechnology

An Outline of the Immunogenic Potential of Progressing SARSCoV- 2 Vaccine Technologies among Children and Adolescents

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles